



Lipid Management in Diabetes

People with type 2 diabetes are at risk of ASCVD similar to those with existing ASCVD. Therefore, lipid management is vital to reduce their risk.



Lipid panel should be obtained:

- At time of diabetes diagnosis and annually
- At initiation and after 4–12 weeks of initiation/adjustment of lipid-lowering drugs

Treatment:

- Lifestyle interventions like weight loss, increase physical activity, reducing
 - saturated and trans fat intake and smoking cessation, and increase intake of omega-3 fatty acids
 - Pharmacotherapy:
 - Statins are first-choice for primary
 - and secondary prevention
 - Ezetimibe, PCSK9i, bempedoic acid, and inclisiran can be used as add-on therapies if not meeting LDL goal on statins or statin-intolerant

Ell For · A for

LDL goals:

For primary prevention: LDL <70 mg/dL

- Age 20–39: with diabetes and other ASCVD risk factors, it is reasonable to treat
- Age 40–75: treat to target
- Age >75: already on statin therapy, it is reasonable to continue. It is also reasonable to initiate moderate-intensity statins after review of risks and benefits

For secondary prevention: LDL <55 mg/dL

Hypertriglyceridemia: Elevated levels increase the risk for pancreatitis and ASCVD

Targeting triglycerides <150 mg/dL


in individuals with ASCVD or at high

risk of it



Moderate hypertriglyceridemia: fasting triglycerides >150 mg/dL or nonfasting >175 mg/dL \rightarrow address lifestyle factors and secondary factors

Severe hypertriglyceridemia: Fasting triglycerides ≥500 should be evaluated for secondary causes



Learn more at Professional.Diabetes.org | 1-800-DIABETES (1-800-342-2383)



Lifestyle interventions like weight loss, alcohol cessation, following a diet lower in carbohydrate and fat

Pharmacotherapy: In addition to statins, fibrate and EPA may be used